Paul-Henri Wicky
- Infectious Diseases top 10%
- Epidemiology
- Neurology
- Molecular Biology
- Molecular Medicine top 10%
- Co-authors
- Jean‐François TimsitÉtienne de MontmollinJuliette PatrierStéphane RucklyNiccolò BuettiPierre JaquetQuentin Le HingratBenoît Visseaux
- Topics
- COVID-19 Clinical Research Studies (6 papers)SARS-CoV-2 and COVID-19 Research (4 papers)Pneumonia and Respiratory Infections (4 papers)
- Journals
- Scientific ReportsAntimicrobial Agents and ChemotherapyJournal of Antimicrobial Chemotherapy
- Partner nations
- FranceSwitzerlandUnited States
In The Last Decade
Paul-Henri Wicky
14 papers receiving 239 citations
Peers
Comparison fields: 5 of 61
- Infectious Diseases 134
- Epidemiology 60
- Neurology 53
- Molecular Biology 39
- Molecular Medicine 37
Countries citing papers authored by Paul-Henri Wicky
This map shows the geographic impact of Paul-Henri Wicky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul-Henri Wicky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul-Henri Wicky more than expected).
Fields of papers citing papers by Paul-Henri Wicky
This network shows the impact of papers produced by Paul-Henri Wicky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul-Henri Wicky. The network helps show where Paul-Henri Wicky may publish in the future.
Co-authorship network of co-authors of Paul-Henri Wicky
This figure shows the co-authorship network connecting the top 25 collaborators of Paul-Henri Wicky. A scholar is included among the top collaborators of Paul-Henri Wicky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul-Henri Wicky. Paul-Henri Wicky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 17 | |
| 3 | 17 | |
| 4 | 6 | |
| 5 | 27 | |
| 6 | 5 | |
| 7 | 4 | |
| 8 | 15 | |
| 9 | 38 | |
| 10 | 11 | |
| 11 | 16 | |
| 12 | 35 | |
| 13 | 17 | |
| 14 | 11 | |
| 15 | 25 |
About Paul-Henri Wicky
Paul-Henri Wicky is a scholar working on Molecular Medicine, Critical Care and Intensive Care Medicine and Applied Microbiology and Biotechnology, having authored 15 papers that have together received 244 indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (6 papers), SARS-CoV-2 and COVID-19 Research (4 papers) and Pneumonia and Respiratory Infections (4 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (22 citations), Molecular Medicine (37 citations) and Infectious Diseases (134 citations). Paul-Henri Wicky has collaborated with scholars based in France, Switzerland and United States. Frequent co-authors include Jean‐François Timsit, Étienne de Montmollin, Juliette Patrier, Stéphane Ruckly, Niccolò Buetti, Pierre Jaquet, Quentin Le Hingrat, Benoît Visseaux, Lila Bouadma and Nadhira Houhou‐Fidouh. Their work appears in journals such as Scientific Reports, Antimicrobial Agents and Chemotherapy and Journal of Antimicrobial Chemotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.